Background: Drug-induced liver injury (Hepatotoxicity) Liver Toxicity Biomarkers Study: Drug pair, tolcapone and entacapone Methods: Design and marker identification strategy Results: Validation (statistics)Susceptible Animals: Clinical variablesSummary. Outline . Background. Hepatotoxicity accounts for ~27% of drugs withdrawn from the market in the period 1960-2002.Hepatotoxicity accounts for over 40% of drug candidate terminations in the clinical phase.An estimate cost due to hepa1140
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.